De­vel­op­ers of a key mR­NA de­liv­ery tech, seek­ing a piece of Mod­er­na's Covid rich­es, sue for patent in­fringe­ment

The law­suit that Mod­er­na has been dread­ing fi­nal­ly got to it.

Ar­bu­tus and Genevant have sued the big biotech for in­fring­ing on their patent on a lipid nanopar­ti­cle plat­form that they say was cru­cial to the de­liv­ery of Mod­er­na’s wide­ly-used Covid-19 vac­cine.

And they want a cut of its multi­bil­lion rich­es.

Among oth­er things, the two com­pa­nies are seek­ing:

An award of dam­ages suf­fi­cient to com­pen­sate Ar­bu­tus and Genevant for Mod­er­na’s in­fringe­ment un­der 35 U.S.C. § 284, in no event less than a rea­son­able roy­al­ty on all in­fring­ing sales or oth­er dis­po­si­tions of Ac­cused Prod­uct.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.